Global Drug Eluting Stents Market 2018-2024
Global Drug-eluting Stents Market – Drivers, Restraints, Opportunities, Trends, and Forecast: 2018–2024
Overview: Drug-eluting stents refer to the metal stents that have a coating of drugs such as paclitaxel, everolimus, and also antiproliferative drugs to widen the narrowed blood vessel. The first-generation DES has raised safety issues due to a higher incidence of stent thrombosis, which has further given rise to biodegradable DES to provide better treatment. The ability to release an antiproliferative drug that avoids neointimal proliferation, which reduces the incidence of stent restenosis and prevent the need of restenting. These benefits contributed to the domination of DES in 2016. However, thrombosis, along with vasomotion, is the major issue that needs to be addressed in the DES market. Drug-eluting stents find importance in cardiovascular complications as it is a minimally invasive surgical procedure, broadens the constricted blood vessels, and is useful in prolonging the life of the patient.
Increasing prevalence of cardiovascular diseases, rising aging population, growing acceptance for minimally invasive endovascular surgeries, and good reimbursement facilities are few of the factors driving the growth of the DES market. Increasing healthcare spending, rise in the number of outpatient procedures, and market expansion opportunities in emerging nations are providing an opportunity for the growth of the market. However, alternatives for drug-eluting stents, lack of skilled healthcare professionals, and stringent regulatory approval process are hampering the growth of the market.
Market Analysis: The “global drug-eluting stents market” is estimated to witness a CAGR of 5.4% during the forecast period 2018–2024. The market is analyzed based on four segments – coating type, applications, end-users, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). Europe accounts for the largest share of the drug-eluting stents market, followed by Europe, Asia Pacific, and Rest of the World. More than 60% of the market is occupied by Europe, with Germany being the major contributor to the market growth.
Coating Type Analysis: Based on the type of coating, the market is segmented into polymer-based coating and polymer-free coating drug-eluting stents. Non-biodegradable and biodegradable polymer are the two types of polymer-based coatings. Microporous surface, microstructured surface, slotted tubular surface, and nanoporous surface are the types of polymer-free coating.
Application Analysis: Based on applications, the market is segmented into coronary artery disease and peripheral artery disease. Approximately 90% of all percutaneous interventional surgeries use a coronary stent of all stenting procedures is done with drug-eluting stents (DES). Therefore, the majority of the market is occupied by coronary arterial intervention.
End-users Analysis: The major end-users in the drug eluting stents market are cardiology centers, ambulatory surgery centers (ASCs), and hospitals. The advantages such as availability of surgery specialists, reduced hospital stay duration, and less charge of surgery have made ambulatory surgical centers the most preferred mode for the treatment. This has made them the largest segment among end-users.
Key Players: Abbott Laboratories, Boston Scientific Corporation, Medtronic PLC, Biotronik SE & Co. KG, MicroPort Scientific Corporation, Terumo Corporation, Biosensors International Group, Meril Life Science, Stentys SA, Cook Medical Inc., and Lepu Medical Technology. Currently, many manufacturers are outsourcing research to clinical research organizations, which is indirectly boosting the growth of the drug-eluting stents market.
Competitive Analysis: New product development, geographical expansion, collaboration, mergers & acquisitions, and pricing strategies are vital undertakings of players in this space. For instance, in May 2018, MicroPort, a Chinese company, acquired the cardiac rhythm management segment of LivaNova, which has made MicroPort a prominent player in the market. In January 2017, St. Jude Medical, one of the major players in the market, was acquired by Abbott Laboratories for a total of $25 billion. In August 2018, Boston Scientific Corp. signed an agreement to acquire Veniti Inc. Recently, the prices of coronary stents in India have been slashed by around 70%, making it affordable to lower-income people. As a result, Abbott and Boston are withdrawing their most advanced products “Absorb” and “Synergy & Promous Premier”, respectively. This has helped MicroPort to establish its market easily in India with the targeted drug-eluting stents. The technology of MicroPort is proved to be no less than Abbott and other products by market leaders. This is expected to strengthen its market in India.
Benefits: The report provides complete details about the usage and adoption rate of drug-eluting stents in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Overview: Drug-eluting stents refer to the metal stents that have a coating of drugs such as paclitaxel, everolimus, and also antiproliferative drugs to widen the narrowed blood vessel. The first-generation DES has raised safety issues due to a higher incidence of stent thrombosis, which has further given rise to biodegradable DES to provide better treatment. The ability to release an antiproliferative drug that avoids neointimal proliferation, which reduces the incidence of stent restenosis and prevent the need of restenting. These benefits contributed to the domination of DES in 2016. However, thrombosis, along with vasomotion, is the major issue that needs to be addressed in the DES market. Drug-eluting stents find importance in cardiovascular complications as it is a minimally invasive surgical procedure, broadens the constricted blood vessels, and is useful in prolonging the life of the patient.
Increasing prevalence of cardiovascular diseases, rising aging population, growing acceptance for minimally invasive endovascular surgeries, and good reimbursement facilities are few of the factors driving the growth of the DES market. Increasing healthcare spending, rise in the number of outpatient procedures, and market expansion opportunities in emerging nations are providing an opportunity for the growth of the market. However, alternatives for drug-eluting stents, lack of skilled healthcare professionals, and stringent regulatory approval process are hampering the growth of the market.
Market Analysis: The “global drug-eluting stents market” is estimated to witness a CAGR of 5.4% during the forecast period 2018–2024. The market is analyzed based on four segments – coating type, applications, end-users, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). Europe accounts for the largest share of the drug-eluting stents market, followed by Europe, Asia Pacific, and Rest of the World. More than 60% of the market is occupied by Europe, with Germany being the major contributor to the market growth.
Coating Type Analysis: Based on the type of coating, the market is segmented into polymer-based coating and polymer-free coating drug-eluting stents. Non-biodegradable and biodegradable polymer are the two types of polymer-based coatings. Microporous surface, microstructured surface, slotted tubular surface, and nanoporous surface are the types of polymer-free coating.
Application Analysis: Based on applications, the market is segmented into coronary artery disease and peripheral artery disease. Approximately 90% of all percutaneous interventional surgeries use a coronary stent of all stenting procedures is done with drug-eluting stents (DES). Therefore, the majority of the market is occupied by coronary arterial intervention.
End-users Analysis: The major end-users in the drug eluting stents market are cardiology centers, ambulatory surgery centers (ASCs), and hospitals. The advantages such as availability of surgery specialists, reduced hospital stay duration, and less charge of surgery have made ambulatory surgical centers the most preferred mode for the treatment. This has made them the largest segment among end-users.
Key Players: Abbott Laboratories, Boston Scientific Corporation, Medtronic PLC, Biotronik SE & Co. KG, MicroPort Scientific Corporation, Terumo Corporation, Biosensors International Group, Meril Life Science, Stentys SA, Cook Medical Inc., and Lepu Medical Technology. Currently, many manufacturers are outsourcing research to clinical research organizations, which is indirectly boosting the growth of the drug-eluting stents market.
Competitive Analysis: New product development, geographical expansion, collaboration, mergers & acquisitions, and pricing strategies are vital undertakings of players in this space. For instance, in May 2018, MicroPort, a Chinese company, acquired the cardiac rhythm management segment of LivaNova, which has made MicroPort a prominent player in the market. In January 2017, St. Jude Medical, one of the major players in the market, was acquired by Abbott Laboratories for a total of $25 billion. In August 2018, Boston Scientific Corp. signed an agreement to acquire Veniti Inc. Recently, the prices of coronary stents in India have been slashed by around 70%, making it affordable to lower-income people. As a result, Abbott and Boston are withdrawing their most advanced products “Absorb” and “Synergy & Promous Premier”, respectively. This has helped MicroPort to establish its market easily in India with the targeted drug-eluting stents. The technology of MicroPort is proved to be no less than Abbott and other products by market leaders. This is expected to strengthen its market in India.
Benefits: The report provides complete details about the usage and adoption rate of drug-eluting stents in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
1 INDUSTRY OUTLOOK
1.1 Industry Overview
1.2 Total Addressable Market
1.3 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market
3.3 Industry Trends
3.4 Related Markets
3.4.1 Cardiovascular Drugs
3.4.1.1 Trends of cardiovascular drugs market
3.4.2 Aortic Aneurysm
3.4.2.1 Trends of Aortic Aneurysm Market
3.4.3 Coronary Stents Market
3.4.4 Cardiovascular Diagnostics
4 MARKET OUTLOOK
4.1 Reimbursement Scenario
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 PEST Analysis
5 MARKET CHARACTERISTICS
5.1 Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing prevalence of cardiovascular diseases
5.1.1.2 Increasing Aging Population
5.1.1.3 Growing acceptance for minimally invasive endovascular surgeries
5.1.2 Opportunities
5.1.2.1 Increase in healthcare spending
5.1.2.2 Increase in the number of outpatient procedures
5.1.2.3 Market expansion opportunities in emerging nations
5.1.3 Restraints
5.1.3.1 Stringent regulations for approval process
5.1.3.2 Alternative treatment for the drug eluting stents
5.1.3.3 Lack of skilled healthcare professionals
5.1.3.4 Stringent Regulatory Approval Process
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 TYPES: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Polymer Based Coating
6.3 Polymer free Coating
7 TECHNOLOGY: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Coronary Artery Diseases
7.3 Peripheral Artery Disease
8 END-USERS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 Hospitals and clinics
8.3 Ambulatory Surgical Center
8.4 Cardiac Centers
9 REGIONS: MARKET SIZE AND ANALYSIS
9.1 Overview
9.2 North America
9.2.1 Overview
9.3 Europe
9.3.1 Overview
9.4 Asia Pacific
9.4.1 Overview
9.5 Rest of the World
9.5.1 Overview
10 COMPETITIVE LANDSCAPE
11 VENDORS PROFILE
11.1 Abbott Laboratories
11.1.1 Overview
11.1.2 Business Unit
11.1.3 Geographic Presence
11.1.4 Business Focus
11.1.5 SWOT Analysis
11.1.6 Business Strategy
11.2 Boston Scientific Corp
11.2.1 Overview
11.2.2 Business Units
11.2.3 Geographic Presence
11.2.4 Business Focus
11.2.5 SWOT Analysis
11.2.6 Business Strategies
11.3 Biotronik, Inc
11.3.1 Overview
11.3.2 Business Focus
11.3.3 SWOT Analysis
11.3.4 Business Strategy
11.4 Medtronic Plc
11.4.1 Overview
11.4.2 Business Units
11.4.3 Geographic Presence
11.4.4 Business Focus
11.4.5 SWOT Analysis
11.4.6 Business Strategies
11.5 Johnson & Johnson
11.5.1 Overview
11.5.2 Business Units
11.5.3 Geographic Revenue
11.5.4 Business Focus
11.5.5 SWOT Analysis
11.5.6 Business Strategies
11.6 MicroPort Scientific Corporation
11.6.1 Overview
11.6.2 Business Units
11.6.3 Geographic Presence
11.6.4 Business Focus
11.6.5 SWOT Analysis
11.6.6 Business Strategies
12 VENDORS PROFILE
12.1 Terumo Corp.
12.1.1 Overview
12.2 Biosensors International Group
12.2.1 Overview
12.3 Meril Life Science
12.3.1 Overview
12.4 STENTYS S.A.
12.4.1 Overview
12.5 Cook Medical Inc
12.5.1 Overview
12.6 Lepu Medical Technology Co., Ltd
12.6.1 Overview
13 ANNEXURE
Abbreviations
1.1 Industry Overview
1.2 Total Addressable Market
1.3 Industry Trends
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market
3.3 Industry Trends
3.4 Related Markets
3.4.1 Cardiovascular Drugs
3.4.1.1 Trends of cardiovascular drugs market
3.4.2 Aortic Aneurysm
3.4.2.1 Trends of Aortic Aneurysm Market
3.4.3 Coronary Stents Market
3.4.4 Cardiovascular Diagnostics
4 MARKET OUTLOOK
4.1 Reimbursement Scenario
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 PEST Analysis
5 MARKET CHARACTERISTICS
5.1 Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing prevalence of cardiovascular diseases
5.1.1.2 Increasing Aging Population
5.1.1.3 Growing acceptance for minimally invasive endovascular surgeries
5.1.2 Opportunities
5.1.2.1 Increase in healthcare spending
5.1.2.2 Increase in the number of outpatient procedures
5.1.2.3 Market expansion opportunities in emerging nations
5.1.3 Restraints
5.1.3.1 Stringent regulations for approval process
5.1.3.2 Alternative treatment for the drug eluting stents
5.1.3.3 Lack of skilled healthcare professionals
5.1.3.4 Stringent Regulatory Approval Process
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 TYPES: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Polymer Based Coating
6.3 Polymer free Coating
7 TECHNOLOGY: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Coronary Artery Diseases
7.3 Peripheral Artery Disease
8 END-USERS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 Hospitals and clinics
8.3 Ambulatory Surgical Center
8.4 Cardiac Centers
9 REGIONS: MARKET SIZE AND ANALYSIS
9.1 Overview
9.2 North America
9.2.1 Overview
9.3 Europe
9.3.1 Overview
9.4 Asia Pacific
9.4.1 Overview
9.5 Rest of the World
9.5.1 Overview
10 COMPETITIVE LANDSCAPE
11 VENDORS PROFILE
11.1 Abbott Laboratories
11.1.1 Overview
11.1.2 Business Unit
11.1.3 Geographic Presence
11.1.4 Business Focus
11.1.5 SWOT Analysis
11.1.6 Business Strategy
11.2 Boston Scientific Corp
11.2.1 Overview
11.2.2 Business Units
11.2.3 Geographic Presence
11.2.4 Business Focus
11.2.5 SWOT Analysis
11.2.6 Business Strategies
11.3 Biotronik, Inc
11.3.1 Overview
11.3.2 Business Focus
11.3.3 SWOT Analysis
11.3.4 Business Strategy
11.4 Medtronic Plc
11.4.1 Overview
11.4.2 Business Units
11.4.3 Geographic Presence
11.4.4 Business Focus
11.4.5 SWOT Analysis
11.4.6 Business Strategies
11.5 Johnson & Johnson
11.5.1 Overview
11.5.2 Business Units
11.5.3 Geographic Revenue
11.5.4 Business Focus
11.5.5 SWOT Analysis
11.5.6 Business Strategies
11.6 MicroPort Scientific Corporation
11.6.1 Overview
11.6.2 Business Units
11.6.3 Geographic Presence
11.6.4 Business Focus
11.6.5 SWOT Analysis
11.6.6 Business Strategies
12 VENDORS PROFILE
12.1 Terumo Corp.
12.1.1 Overview
12.2 Biosensors International Group
12.2.1 Overview
12.3 Meril Life Science
12.3.1 Overview
12.4 STENTYS S.A.
12.4.1 Overview
12.5 Cook Medical Inc
12.5.1 Overview
12.6 Lepu Medical Technology Co., Ltd
12.6.1 Overview
13 ANNEXURE
Abbreviations
TABLES
TABLE 1 TOP ACQUISITIONS IN CARDIOVASCULAR INDUSTRY
TABLE 1 DRUG-ELUTING CORONARY STENT WITH ANGIOPLASTY
TABLE 2 DRUG-ELUTING CORONARY STENT WITH ATHERECTOMY
TABLE 3 DRUG-ELUTING STENT - BYPASS GRAFT REVASCULARIZATION
TABLE 4 DRUG-ELUTING CORONARY STENT - CHRONIC TOTAL OCCLUSION REVASCULARIZATION
TABLE 5 DRUG ELUTING STENTS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION)
TABLE 6 GLOBAL CORONARY STENTS PIPELINE
TABLE 7 DRUG ELUTING STENTS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION)
TABLE 8 OTHER PROMINENT VENDORS OF DRUG ELUTING STENTS MARKET
TABLE 2 ABBOTT LABORATORIES: PRODUCT OFFERINGS
TABLE 3 ABBOTT LABORATORIES: RECENT DEVELOPMENTS
TABLE 9 BOSTON SCIENTIFIC CORP: OFFERINGS
TABLE 10 BOSTON SCIENTIFIC CORP: RECENT DEVELOPMENTS
TABLE 4 BIOTRONIK INC: PRODUCT OFFERINGS
TABLE 5 BIOTRONIK INC: RECENT DEVELOPMENTS
TABLE 11 MEDTRONIC PLC: OFFERINGS
TABLE 12 MEDTRONIC PLC: RECENT DEVELOPMENTS
TABLE 13 JOHNSON & JOHNSON: PRODUCT OFFERINGS
TABLE 14 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
TABLE 15 MICROPORT SCIENTIFIC: OFFERINGS
TABLE 16 MICROPORT SCIENTIFIC CORPORATION: RECENT DEVELOPMENTS
TABLE 17 TERUMO CORP.: RECENT DEVELOPMENTS
TABLE 18 BIOSENSORS INTERNATIONAL GROUP: RECENT DEVELOPMENTS
TABLE 19 STENTYS S.A.: RECENT DEVELOPMENTS
TABLE 20 COOK MEDICAL INC: OVERVIEW
TABLE 21 COOK MEDICAL INC.: RECENT DEVELOPMENTS
TABLE 22 LEPU MEDICAL TECHNOLOGY CO., LTD: OVERVIEW
TABLE 23 LEPU MEDICAL TECHNOLOGY CO., LTD.: RECENT DEVELOPMENTS
CHARTS
CHART 1 GLOBAL MEDICAL DEVICES MARKET SEGMENTATION
CHART 2 GLOBAL CARDIOVASCULAR DISEASE MARKET 2017 ($BILLION)
CHART 3 RESEARCH METHODOLOGY OF GLOBAL DRUG ELUTING STENTS MARKET
CHART 4 GLOBAL DRUG ELUTING STENTS MARKET REVENUE, 2017-2024 ($MILLION)
CHART 5 SEGMENTATION OF GLOBAL DRUG ELUTING STENTS MARKET
CHART 6 PORTER 5 FORCES OF GLOBAL DRUG ELUTING STENTS MARKET
CHART 7 PEST ANALYSIS OF DRUG ELUTING STENTS MARKET
CHART 8 MARKET DYNAMICS – DRO ANALYSIS
CHART 9 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960-2060 (%)
CHART 10 DRO – IMPACT ANALYSIS OF GLOBAL PACEMAKERS MARKET
CHART 11 KEY STAKEHOLDERS
CHART 12 DRUG ELUTING STENTS MARKET SEGMENT REVENUE BY TYPES, 2017
CHART 13 DRUG ELUTING STENTS MARKET SEGMENT SHARE BY TECHNOLOGY, 2017 (%)
CHART 14 DRUG ELUTING STENTS MARKET REVENUE IN CORONARY ARTERY DISEASES APPLICATION, 2017-2024 ($MILLION)
CHART 15 DRUG ELUTING STENTS MARKET REVENUE IN PERIPHERAL ARTERY DISEASES APPLICATION, 2017-2024 ($MILLION)
CHART 16 GLOBAL DRUG ELUTING STENTS MARKET BY END-USER SEGMENTATION, 2017
CHART 17 DRUG ELUTING STENTS MARKET BY REGIONAL SEGMENTATION, 2017 (%)
CHART 18 DRUG ELUTING STENTS MARKET REVENUE IN NORTH AMERICA, 2017-2024 ($MILLION)
CHART 19 DRUG ELUTING STENTS MARKET REVENUE IN EUROPE, 2017-2024 ($MILLION)
CHART 20 DURG ELUTING STENTS MARKET REVENUE IN ASIA PACIFIC, 2017-2024 ($MILLION)
CHART 21 DRUG ELUTING STENTS MARKET REVENUE IN REST OF THE WORLD, 2017-2024 ($MILLION)
CHART 22 ABBOTT LABORATORIES.: OVERVIEW SNAPSHOT
CHART 23 ABBOTT LABORATORIES.: BUSINESS UNITS
CHART 24 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE
CHART 25 ABBOTT LABORATORIES.: SWOT ANALYSIS
CHART 26 BOSTON SCIENTIFIC CORP.: OVERVIEW SNAPSHOT
CHART 27 BOSTON SCIENTIFIC CORP.: BUSINESS UNITS
CHART 28 BOSTON SCIENTIFIC CORP.: GEOGRAPHIC PRESENCE
CHART 29 BOSTON SCIENTIFIC CORP: SWOT ANALYSIS
CHART 30 BIOTRONIK INC.: SWOT ANALYSIS
CHART 31 MEDTRONIC PLC: OVERVIEW SNAPSHOT
CHART 32 MEDTRONIC PLC: BUSINESS UNITS
CHART 33 MEDTRONIC PLC: GEOGRAPHIC PRESENCE
CHART 34 MEDTRONIC PLC: SWOT ANALYSIS
CHART 35 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
CHART 36 JOHNSON & JOHNSON: BUSINESS UNITS
CHART 37 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
CHART 38 JOHNSON & JOHNSON: SWOT ANALYSIS
CHART 39 MICROPORT SCIENTIFIC CORPORATION: OVERVIEW SNAPSHOT
CHART 40 MICROPORT SCIENTIFIC CORPORATION: BUSINESS UNITS
CHART 41 MICROPORT SCIENTIFIC CORPORATION: GEOGRAPHIC PRESENCE
CHART 42 MICROPORT SCIENTIFIC CORPORATION: SWOT ANALYSIS
TABLE 1 TOP ACQUISITIONS IN CARDIOVASCULAR INDUSTRY
TABLE 1 DRUG-ELUTING CORONARY STENT WITH ANGIOPLASTY
TABLE 2 DRUG-ELUTING CORONARY STENT WITH ATHERECTOMY
TABLE 3 DRUG-ELUTING STENT - BYPASS GRAFT REVASCULARIZATION
TABLE 4 DRUG-ELUTING CORONARY STENT - CHRONIC TOTAL OCCLUSION REVASCULARIZATION
TABLE 5 DRUG ELUTING STENTS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION)
TABLE 6 GLOBAL CORONARY STENTS PIPELINE
TABLE 7 DRUG ELUTING STENTS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION)
TABLE 8 OTHER PROMINENT VENDORS OF DRUG ELUTING STENTS MARKET
TABLE 2 ABBOTT LABORATORIES: PRODUCT OFFERINGS
TABLE 3 ABBOTT LABORATORIES: RECENT DEVELOPMENTS
TABLE 9 BOSTON SCIENTIFIC CORP: OFFERINGS
TABLE 10 BOSTON SCIENTIFIC CORP: RECENT DEVELOPMENTS
TABLE 4 BIOTRONIK INC: PRODUCT OFFERINGS
TABLE 5 BIOTRONIK INC: RECENT DEVELOPMENTS
TABLE 11 MEDTRONIC PLC: OFFERINGS
TABLE 12 MEDTRONIC PLC: RECENT DEVELOPMENTS
TABLE 13 JOHNSON & JOHNSON: PRODUCT OFFERINGS
TABLE 14 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
TABLE 15 MICROPORT SCIENTIFIC: OFFERINGS
TABLE 16 MICROPORT SCIENTIFIC CORPORATION: RECENT DEVELOPMENTS
TABLE 17 TERUMO CORP.: RECENT DEVELOPMENTS
TABLE 18 BIOSENSORS INTERNATIONAL GROUP: RECENT DEVELOPMENTS
TABLE 19 STENTYS S.A.: RECENT DEVELOPMENTS
TABLE 20 COOK MEDICAL INC: OVERVIEW
TABLE 21 COOK MEDICAL INC.: RECENT DEVELOPMENTS
TABLE 22 LEPU MEDICAL TECHNOLOGY CO., LTD: OVERVIEW
TABLE 23 LEPU MEDICAL TECHNOLOGY CO., LTD.: RECENT DEVELOPMENTS
CHARTS
CHART 1 GLOBAL MEDICAL DEVICES MARKET SEGMENTATION
CHART 2 GLOBAL CARDIOVASCULAR DISEASE MARKET 2017 ($BILLION)
CHART 3 RESEARCH METHODOLOGY OF GLOBAL DRUG ELUTING STENTS MARKET
CHART 4 GLOBAL DRUG ELUTING STENTS MARKET REVENUE, 2017-2024 ($MILLION)
CHART 5 SEGMENTATION OF GLOBAL DRUG ELUTING STENTS MARKET
CHART 6 PORTER 5 FORCES OF GLOBAL DRUG ELUTING STENTS MARKET
CHART 7 PEST ANALYSIS OF DRUG ELUTING STENTS MARKET
CHART 8 MARKET DYNAMICS – DRO ANALYSIS
CHART 9 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960-2060 (%)
CHART 10 DRO – IMPACT ANALYSIS OF GLOBAL PACEMAKERS MARKET
CHART 11 KEY STAKEHOLDERS
CHART 12 DRUG ELUTING STENTS MARKET SEGMENT REVENUE BY TYPES, 2017
CHART 13 DRUG ELUTING STENTS MARKET SEGMENT SHARE BY TECHNOLOGY, 2017 (%)
CHART 14 DRUG ELUTING STENTS MARKET REVENUE IN CORONARY ARTERY DISEASES APPLICATION, 2017-2024 ($MILLION)
CHART 15 DRUG ELUTING STENTS MARKET REVENUE IN PERIPHERAL ARTERY DISEASES APPLICATION, 2017-2024 ($MILLION)
CHART 16 GLOBAL DRUG ELUTING STENTS MARKET BY END-USER SEGMENTATION, 2017
CHART 17 DRUG ELUTING STENTS MARKET BY REGIONAL SEGMENTATION, 2017 (%)
CHART 18 DRUG ELUTING STENTS MARKET REVENUE IN NORTH AMERICA, 2017-2024 ($MILLION)
CHART 19 DRUG ELUTING STENTS MARKET REVENUE IN EUROPE, 2017-2024 ($MILLION)
CHART 20 DURG ELUTING STENTS MARKET REVENUE IN ASIA PACIFIC, 2017-2024 ($MILLION)
CHART 21 DRUG ELUTING STENTS MARKET REVENUE IN REST OF THE WORLD, 2017-2024 ($MILLION)
CHART 22 ABBOTT LABORATORIES.: OVERVIEW SNAPSHOT
CHART 23 ABBOTT LABORATORIES.: BUSINESS UNITS
CHART 24 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE
CHART 25 ABBOTT LABORATORIES.: SWOT ANALYSIS
CHART 26 BOSTON SCIENTIFIC CORP.: OVERVIEW SNAPSHOT
CHART 27 BOSTON SCIENTIFIC CORP.: BUSINESS UNITS
CHART 28 BOSTON SCIENTIFIC CORP.: GEOGRAPHIC PRESENCE
CHART 29 BOSTON SCIENTIFIC CORP: SWOT ANALYSIS
CHART 30 BIOTRONIK INC.: SWOT ANALYSIS
CHART 31 MEDTRONIC PLC: OVERVIEW SNAPSHOT
CHART 32 MEDTRONIC PLC: BUSINESS UNITS
CHART 33 MEDTRONIC PLC: GEOGRAPHIC PRESENCE
CHART 34 MEDTRONIC PLC: SWOT ANALYSIS
CHART 35 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
CHART 36 JOHNSON & JOHNSON: BUSINESS UNITS
CHART 37 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
CHART 38 JOHNSON & JOHNSON: SWOT ANALYSIS
CHART 39 MICROPORT SCIENTIFIC CORPORATION: OVERVIEW SNAPSHOT
CHART 40 MICROPORT SCIENTIFIC CORPORATION: BUSINESS UNITS
CHART 41 MICROPORT SCIENTIFIC CORPORATION: GEOGRAPHIC PRESENCE
CHART 42 MICROPORT SCIENTIFIC CORPORATION: SWOT ANALYSIS
